



ALCMI: HELPING TO TRANSFORM THE STANDARD OF CARE FOR LUNG CANCER

ALCMI is a patient-founded, patient-focused research consortium. Its goal is to make Lung Cancer a survivable disease.

ALCMI was created in 2008 as a partner of the Bonnie J. Addario Lung Cancer Foundation (BJALCF) after being identified as a crucial need by more than 70 of the world's leading Lung Cancer researchers, clinicians and patients at a BJALCF-sponsored Summit held in late 2007. These thought leaders unanimously concluded that the collection and analysis of tissue and blood samples from Lung Cancer patients are essential to research and to the development of individually tailored (and more effective) therapies.

ALCMI is unique. It is a comprehensively *contracted* consortium with shared infrastructures (standardized contracts, data systems and biorepositories) and centrally coordinated scientific planning. ALCMI's researchers are pooling their knowledge, specimens and data in order to improve the understanding of the molecular bases of Lung Cancer and to accelerate the development and delivery of much more effective, targeted drugs and treatments tailored to individual patients.

ALCMI represents a paradigm shift in the approach to making Lung Cancer a manageable disease. It is about finding solutions NOW. Not tomorrow. Not for future patients. ALCMI is making a difference—right NOW.



"Empowered patients live longer!!! Our message is simple... We want to live."

—Bonnie J. Addario, Survivor and Founder

ALCMI Board of Directors

Tony Addario
Board Chair & CEO

Scott Santarella
Board Vice Chair
President & CEO: American Lung Association—NY Chapter

Bonnie J. Addario
Lung Cancer Survivor
Founder: BJALCF & ALCMI

Sam Bain
Founder, CEO, Managing Director: Bainco International Investors

Jamie Gorenberg
Writer/Producer: Entertainment Industry

Bruce Gellman
Cancer Survivor, Executive: Communications Industry

Pankaj Patel
Vice President of Marketing: Cisco Systems

Staff

Steven Young
President & COO

Wells Whitney, ScD
Treasurer

Dan Trump, Esq.
Secretary
Partner: Trump Alioto, Trump & Prescott


How to give...

A donation to BJALCF or ALCMI is a gift for patients and their families by supporting our efforts to increase survival through our unprecedented work and research.


<http://lungcancerfoundation.org/donate>

For more information on collaboration and funding opportunities, please contact:
Steven Young at syoung@alcmi.net
or Sheila Von Driska at sheila@lungcancerfoundation.org

BJALCF/ALCMI
1100 Industrial Road, Suite 1, San Carlos, CA 94070
ph 650.598.2857 fx 650.598.0282
lungcancerfoundation.org • alcmi.net




With the ultimate goal of *significantly* impacting survival, ALCMI catalyzes and accelerates the discovery, development and delivery of new and more effective treatment options for all Lung Cancer patients.





A Partnership that Works



ACCELERATE THE SCIENCE

THE research consortium

includes many of the most established thought leaders in Lung Cancer—focused solely on significantly impacting the inexcusable 15.5% 5-year survival rate and ultimately turning Lung Cancer into a survivable disease.



SURVIVE LUNG CANCER

THE patient-focused voice

relentlessly works to increase the survival of Lung Cancer worldwide through early detection, awareness and funding for research.

THE NEW STANDARD OF CARE FOR EVERYONE, EVERYWHERE

ALCMI and BJALCF are committed to improving the standard of care for patients diagnosed with Lung Cancer and people yet to be diagnosed. We recognize the vital importance of molecular testing to develop personalized therapies, and of translating laboratory science into personalized care for patients and their families.

Everyone deserves the best possible options RIGHT NOW to turn their Lung Cancer into a manageable, survivable disease.

FIRST PROJECT: CASTLE COLLABORATIVE ADVANCED STAGE TISSUE LUNG CANCER NETWORK

ALCMI is already helping to revolutionize the current standard of care for Lung Cancer patients through its inaugural collaborative research project termed CASTLE. This clinical trial was launched in November 2010 and is collecting tumor tissues, blood and clinical data from advanced stage Lung Cancer patients. ALCMI offers this one-of-a-kind research resource for investigators around the globe.

What makes CASTLE unique?

- At therapeutic decision points, highly annotated, prospective tumor and blood samples are collected**
 - Enrolled subjects are followed over the long term
 - A biorepository of DNA, RNA and proteins will be linked with patient outcomes data via web-based tools
- CASTLE provides a broad-based, clinically-validated panel of biomarkers and partnerships with diagnostic laboratories**
 - A dynamic biomarker panel will evolve
 - Tissue collections will enable reanalyses as new molecular markers and mutations are discovered
- CASTLE bridges the gap**
 - CASTLE provides immediate access to technologies, information and data to treating physicians and community health providers leading to better outcomes for patients via customized treatments—consequently treating the person rather than just the disease
 - CASTLE will have a registry of tissue like no other in the world, available not only to investigators in the United States, but worldwide

“One of the things I like best about this initiative is the fact that we provide real-time information back to patients and their providers. This is not just a banking initiative where we collect data with the intent to publish years from now.”

—Dr. David Carbone
Scientific Leadership Board Chair

Scientific Leadership Board

David Carbone, MD, PhD
Chair
Vanderbilt University

Ite Laird-Offringa, PhD
University of Southern California

Bonnie J. Addario
BJALCF & ALCMI

Harvey Pass, MD
New York University

David Gandara, MD
UC Davis

Rafael Rosell, MD, PhD
Catalan Institute of Oncology

David Jablons, MD
UC San Francisco

Giorgio Scagliotti, MD, PhD
University of Turino, Italy

Pasi Jänne, MD, PhD
Dana-Farber Cancer Institute

Collaborating Institutions

Alta Bates Summit Medical Center—Oakland, CA
 Catalan Institute of Oncology—Barcelona, Spain
 Dana-Farber Cancer Institute—Boston, MA
 Hoag Cancer Institute—Newport Beach, CA
 Lahey Clinic—Burlington, MA
 New York University—New York, NY
 UC Davis—Sacramento, CA
 UC San Francisco—San Francisco, CA
 University of Southern California, Los Angeles, CA
 University of Turino—Turino, Italy
 Vanderbilt University—Nashville, TN

“Prior to the formation of ALCMI, less than 20% of diagnosed Lung Cancer patients were benefitting from molecular testing. Hopefully this is the beginning of personalized medicine for Lung Cancer patients and Hoag is proud to be the first community hospital to participate as a collaborator in ALCMI.”

—Robert O. Dillman, M.D., F.A.C.P.
Executive Medical and Scientific Director
Hoag Cancer Institute